Source comparison
Does Thymosin Alpha-1 Help Infection Defense Research?: Research vs Clinical Comparison
Chronic Hepatitis B Research HBeAg seroconversion, viral load reduction High (22 RCTs, n=2,400) 24–48 weeks, 1.6mg twice weekly SC 28% improvement vs antiviral alone Strong evidence. Thymosin alpha-1 enhances immune-mediated viral clearance when combined with
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B Research
- HBeAg seroconversion, viral load reduction
- High (22 RCTs, n=2,400)
- 24–48 weeks, 1.6mg twice weekly SC
- 28% improvement vs antiviral alone
- Strong evidence. Thymosin alpha-1 enhances immune-mediated viral clearance when combined with nucleoside analogs
- Sepsis-Induced Immunosuppression
- HLA-DR restoration, secondary infection rates
- Moderate (8 trials, n=640)
- 7–14 days, 1.6mg daily IV
- 34% reduction in VAP incidence
- Promising but requires larger Phase III validation. Most trials underpowered for mortality endpoints
- Influenza A (Murine Models)
- Viral titer reduction, survival rates
- Preclinical only
- 5–10 days, 100–200 mcg/kg SC
- 72% viral titer reduction (24h admin), 31% (72h admin)
- Timing-dependent effects suggest prophylactic or very early intervention value. Human translation uncertain
- Fungal Infections (Neutropenic Models)
- Fungal burden, neutrophil recovery
- Low (3 small trials, n=120)
- 14–21 days, 1.6mg twice weekly
- No significant reduction in fungal load as monotherapy
- Limited utility as standalone. May enhance outcomes when combined with antifungals in high-risk populations
- Hepatitis C (Pre-DAA Era)
- Sustained virological response
- Moderate (14 trials, n=1,100)
- 24 weeks, 1.6–3.2mg twice weekly
- 18% improvement vs interferon alone
- Largely superseded by direct-acting antivirals. Historical relevance for immune modulation mechanisms